A meta-analysis reveals prognostic role of programmed death ligand-1 in Asian patients with non-small cell lung cancer.
10.1007/s11596-016-1585-8
- Author:
Xiao-Yan HU
1
;
Wei ZHANG
2
;
Yue HU
1
;
Yong ZHANG
3
;
Rui GONG
1
;
Jin-Yan LIANG
1
;
Li LIU
4
Author Information
1. Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.
2. Department of Radiology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China.
3. Department of Radiation Oncology, Hubei Cancer Hospital, Wuhan, 430079, China.
4. Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China. liulixiehe2004@163.com.
- Publication Type:Journal Article
- Keywords:
clinicopathologic factors;
meta-analysis;
non-small cell lung cancer;
overall survival
- MeSH:
Asian Continental Ancestry Group;
B7-H1 Antigen;
genetics;
metabolism;
Biomarkers, Tumor;
genetics;
metabolism;
Carcinoma, Non-Small-Cell Lung;
diagnosis;
ethnology;
genetics;
mortality;
European Continental Ancestry Group;
Humans;
Lung Neoplasms;
diagnosis;
ethnology;
genetics;
mortality;
Neoplasm Grading;
Neoplasm Staging;
Prognosis;
Proportional Hazards Models;
Protein Transport;
Receptor Protein-Tyrosine Kinases;
genetics;
metabolism
- From:
Journal of Huazhong University of Science and Technology (Medical Sciences)
2016;36(3):313-320
- CountryChina
- Language:English
-
Abstract:
Accumulating studies explored the clinicopathologic and prognostic value of programmed death ligand-1 (PD-L1) in non-small cell lung cancer (NSCLC), but the results were controversial. We therefore conducted a meta-analysis to evaluate the predictive role of PD-L1 in NSCLC patients. We systematically collected relevant studies from PubMed, Embase, Web of Science and China National Knowledge Infrastructure. The pooled hazard ratios (HRs) with 95% confidence intervals (CIs) for overall survival (OS), and odd ratios (ORs) with 95% CIs for clinicopathologic factors were calculated. A total of 15 studies involving 3605 patients were included in this meta-analysis. The results showed no prognostic role of PD-L1 in the whole patients (HR=1.60, 95% CI: 0.88-2.89, P=0.123). Subgroup analysis showed that PD-L1 was associated with decreased OS in Asian patients (HR=2.00, 95% CI: 1.55-2.57, P<0.001). Among all the clinicopathologic factors, PD-L1 overexpression was significantly in relevance with poor tumor cell differentiation (HR=1.84, 95% CI: 1.49-2.28, P<0.001), late stage (HR=1.21, 95% CI: 1.02-1.43, P=0.026) and anaplastic lymphoma kinase (ALK) translocation (HR=2.63, 95% CI: 1.08-6.40, P=0.034), but not with other factors. In conclusion, our meta-analysis demonstrated that PD-L1 has a prognostic role in Asian patients with NSCLC.
